Stocksigma LogoStocksigma Logo

Beta Drugs Reports Strong H1 FY27 Performance with 29% Topline Growth

Beta Drugs posted strong H1 FY27 results, with revenue rising 29.2% YoY to INR 263 Cr and PAT increasing to INR 34 Cr (13.1% margin)

Beta Drugs Reports Strong H1 FY27 Performance with 29% Topline Growth

Beta Drugs Ltd 路 Intimation 路 22 Oct 2026, 5:41 pm

Beta Drugs Reports Strong H1 FY27 Performance with 29% Topline Growth Beta Drugs posted strong H1 FY27 results, with revenue rising 29.2% YoY to INR 263 Cr and PAT increasing to INR 34 Cr (13.1% margin). EBITDA grew to INR 61 Cr with margins improving slightly to 23.2%, while gross margin expanded to 56.2% and ROCE reached 23.3%. Segment-wise, CMO led with INR 95 Cr (+21% YoY), Branded Products generated INR 71 Cr (+17% YoY), Exports rose to INR 43 Cr with 35 approvals, and Nivian surged 75% YoY to INR 31 Cr. Total borrowings declined significantly to INR 49 Cr.

Original exchange filing (PDF)

More announcements from Beta Drugs Ltd

All Beta Drugs Ltd announcements